These effects were blocked by gastrin-receptor antagonists (Smith et al, 1995), such as gastrazole (Roberts et al, 2002), which in a small randomised controlled trial increased the survival time among pancreatic cancer patients (Chau et al, 2006) Other studies refute this theory (Chu et al, 1997). The gene discussed is CCKBR; the disease is pancreatic neoplasm.